SB 652, the “Protecting Patients from Deceptive Drug Ads Act,” would create new federal restrictions and enforcement tools aimed at prescription drug promotion on social media and through telehealth-related marketing. The bill would amend the Federal Food, Drug, and Cosmetic Act to make social media influencers and health care providers liable for civil penalties if they knowingly or recklessly make false or misleading communications about prescription drugs in paid or otherwise financially beneficial promotional posts. It defines covered false or misleading communications to include inaccurate statements, material omissions, or failure to include required brief-summary safety information such as side effects, contraindications, and effectiveness, while carving out bona fide patient care, medical research, and personal experience or opinion statements.
The bill also directs the Secretary of Health and Human Services to issue guidance within 180 days on how the new standard will be administered, including what kinds of statements or omissions count as misleading and how platform-specific factors will be considered. In addition, it expands certain prescription drug advertising disclosure requirements to telehealth companies and similar entities that connect patients with prescribers or dispensers, and requires FDA regulations to be updated within one year. The bill further treats certain payments related to promotion of covered drugs as reportable transfers of value under the federal Open Payments system, making payments to or from social media influencers, telehealth companies, and health care providers publicly reportable when tied to covered drugs.
Beyond enforcement, SB 652 authorizes FDA market surveillance of prescription drug promotion on social media, including use of artificial intelligence tools, staff expansion, coordination with the Federal Trade Commission, and public education efforts. It also allows FDA to notify drug manufacturers when it identifies noncompliant influencer or provider communications and requires public reporting to Congress and the public on enforcement and surveillance activities. The bill authorizes $15 million annually for fiscal years 2025 through 2029 to carry out these activities.
The general sentiment reflected in the bill text and context is strongly consumer-protective and focused on reducing deceptive pharmaceutical marketing, especially in digital spaces where advertising can spread quickly and appear more personal or trustworthy. The bipartisan introduction by Senators Durbin and Marshall suggests an effort to address a shared concern about misleading drug promotion rather than a purely partisan initiative. No committee debate or vote history is provided, so there is no recorded opposition or support in the supplied materials beyond the bill’s introduction and referral.
The main points of contention likely concern how broadly “false or misleading” communications would be interpreted, whether the bill could chill legitimate patient education, medical commentary, or influencer speech, and how the new requirements would apply to telehealth and social media platforms. The bill attempts to limit those concerns by excluding bona fide patient care, medical research, and personal experience statements, and by directing HHS to issue guidance on compliance and platform-specific factors. Potentially affected parties include drug manufacturers, health care providers, telehealth companies, social media influencers, FDA, FTC, and social media platforms.
SB 652 would amend the Federal Food, Drug, and Cosmetic Act and related reporting rules to extend federal oversight of prescription drug promotion into social media and telehealth marketing. It would create a new civil penalty framework for misleading paid drug promotions by influencers and providers, expand advertising disclosure obligations for telehealth-linked promotional activity, and require Open Payments-style reporting for certain promotional payments involving covered drugs. The bill would also direct FDA to conduct surveillance, issue guidance, update regulations, and publicly report enforcement actions, thereby increasing federal regulatory and compliance obligations for manufacturers, providers, platforms, and digital marketers.
The bill appears to have a generally favorable, patient-protection-oriented framing, with its title and structure emphasizing transparency and prevention of deceptive drug advertising. The bipartisan sponsorship by Senators Durbin and Marshall suggests at least initial cross-party interest in addressing misleading pharmaceutical promotion. Because no committee transcript or vote record is provided, there is no documented floor or committee sentiment beyond the bill’s introduction and referral, but the text indicates a clear policy preference for stronger oversight rather than deregulation.
Likely areas of contention include the scope of liability for influencers and health care providers, the definition of “false or misleading communications,” and whether the bill could inadvertently restrict legitimate medical discussion, patient testimony, or educational content. Telehealth companies and social media platforms may also object to the compliance burden, reporting requirements, and FDA surveillance authority, while supporters would likely argue these tools are necessary to curb deceptive marketing and protect patients. The bill’s explicit carveouts for bona fide patient care, medical research, and personal experience suggest lawmakers anticipated concerns about overbreadth and free-speech implications.